17:45 , May 11, 2018 |  BC Week In Review  |  Clinical News

Sol-Gel's acne candidate meets in Phase II

In February, Sol-Gel Technologies Ltd. (NASDAQ:SLGL) said once-daily low- and high-dose topical cream TWIN (S6G5T) both met the three co-primary endpoints compared with vehicle in a Phase II trial in 726 patients with acne. Data...
17:44 , May 11, 2018 |  BC Week In Review  |  Clinical News

Sol-Gel reports Phase II data for Epsolay in rosacea

In February, Sol-Gel Technologies Ltd. (NASDAQ:SLGL) said once-daily Epsolay (formerly VERED) met the co-primary endpoints in a Phase II trial in 92 patients with rosacea. Data from the double-blind, U.S. trial were presented at the...
20:36 , Feb 2, 2018 |  BC Week In Review  |  Financial News

Sol-Gel raises $75M in IPO

Dermatology company Sol-Gel Technologies Ltd. (NASDAQ:SLGL) raised $75 million after market hours on Jan. 31 through the sale of 6.3 million shares at $12 in an IPO. The offering was underwritten by Jefferies, BMO Capital...
02:29 , Feb 1, 2018 |  BC Extra  |  Financial News

Sol-Gel raises $75M in IPO

Dermatology company Sol-Gel Technologies Ltd. (NASDAQ:SLGL) was up $1.64 (14%) to $13.64 on Thursday after raising $75 million late Wednesday through the sale of 6.3 million shares at $12 in an IPO. The offering was...
07:00 , Jul 18, 2016 |  BC Week In Review  |  Clinical News

Adapalene 0 regulatory update

Galderma said Japan approved Epiduo adapalene/benzoyl peroxide to treat acne vulgaris. Galderma expects partner Maruho to launch the once-daily gel formulation of 0.1% adapalene and 2.5% benzoyl peroxide in the country this year. Earlier this...
07:00 , Sep 7, 2015 |  BC Week In Review  |  Company News

Galderma sales and marketing update

Galderma launched Epiduo Forte adapalene/benzoyl peroxide in the U.S. to treat acne vulgaris. The wholesale acquisition cost (WAC) for 45 g of the product is $398.10. Epiduo Forte is a once-daily topical gel formulation...
07:00 , Aug 3, 2015 |  BC Week In Review  |  Clinical News

Epiduo Forte adapalene 0 regulatory update

FDA approved an NDA from Galderma for Epiduo Forte adapalene/benzoyl peroxide to treat acne vulgaris. The company said it plans to launch the once-daily topical gel formulation of adapalene 0.3%, a synthetic retinoid, and benzoyl...
07:00 , Apr 6, 2015 |  BC Week In Review  |  Clinical News

Adapalene 0: Phase III data

A double-blind Phase III trial in 503 patients ages >=12 with moderate to severe acne showed that once-daily 0.3% A/BPO met the co-primary endpoints of improving the success rate (33.7% vs. 11%, p<0.001) and of...
08:00 , Dec 22, 2014 |  BC Week In Review  |  Clinical News

Onexton Gel clindamycin phosphate/benzoyl peroxide regulatory update

FDA approved Onexton Gel clindamycin phosphate/benzoyl peroxide from Valeant to treat acne vulgaris in patients ages =12 years. Valeant said it plans to launch the fixed combination of 1.2% clindamycin phosphate and 3.75% benzoyl peroxide...
07:00 , Aug 11, 2014 |  BioCentury  |  Strategy

Profusion of exclusions

Express Scripts Holding Co.'s 2015 formulary exclusions offer hope that companies can renegotiate once-excluded drugs back into coverage. But the pharmacy benefits manager appears to be expanding the number of drugs and drug classes it...